Efficacy of subthreshold micropulse laser combined with ranibizumab in the treatment of diabetic macular edema

Simple item page
dc.contributor.authorBıçak F.
dc.contributor.authorKayıkçıoğlu Ö.R.
dc.contributor.authorAltınışık M.
dc.contributor.authorDoğruya S.
dc.contributor.authorKurt E.
dc.date.accessioned2024-07-22T08:03:41Z
dc.date.available2024-07-22T08:03:41Z
dc.date.issued2022
dc.description.abstractPurpose: In this study, we aimed to evaluate and compare the visual acuity, macular volume, central macular thickness, change in number of intravitreal ranibizumab injections with micropulse laser applications after loading dose of anti-VEGF to DME patients. Study Design: Retrospective study. Methods: This study was carried out on 97 patients (45 ranibizumab and 52 micropulse grid laser+ranibizumab) with diabetic macular edema patients who were followed in the Retina Unit. At the control visit after three loading ranibizumab injections administered once a month, micropulse grid laser was applied to one group and ranibizumab injection was continued PRN to both groups for an average of 9.27 ± 2.42 months and central macular thickness, macular volume and visual acuity were recorded. Results: There was no significant difference between the groups in terms of gender, smoking and systemic diseases, initial central macular thickness, macular volume and visual acuity measurements (p > 0.05). Central macular thickness, macular volume and visual acuity values measured at the last follow-up of the patients were not significantly different between the groups (p > 0.05). The mean post-treatment injection requirement was 4.19 ± 1.01 for the ranibizumab with micropulse laser combination group and 5.53 ± 1.14 for the ranibizumab group (p < 0.001). Conclusion: Micropulse laser treatment after initial loading doses reduces the need for anti-VEGF injections. There is no deleterious effect on visual acuity and retinal imagings. Therefore, while combination therapy provides an effective treatment, it can also reduce the risk of complications of intravitreal anti-VEGF injections. Studies with the participation of more patients may help in the selection of treatment methods by comparing micropulse laser combined with different injection protocols. © 2022, The Author(s), under exclusive licence to Springer Nature B.V.
dc.identifier.DOI-ID10.1007/s10792-022-02403-5
dc.identifier.issn01655701
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12387
dc.language.isoEnglish
dc.publisherSpringer Science and Business Media B.V.
dc.subjectAngiogenesis Inhibitors
dc.subjectDiabetes Mellitus
dc.subjectDiabetic Retinopathy
dc.subjectHumans
dc.subjectIntravitreal Injections
dc.subjectLaser Coagulation
dc.subjectLasers
dc.subjectMacular Edema
dc.subjectRanibizumab
dc.subjectRetrospective Studies
dc.subjectTomography, Optical Coherence
dc.subjectTreatment Outcome
dc.subjecthemoglobin A1c
dc.subjectproxymetacaine
dc.subjectranibizumab
dc.subjectangiogenesis inhibitor
dc.subjectranibizumab
dc.subjectadult
dc.subjectArticle
dc.subjectbest corrected visual acuity
dc.subjectcentral macular thickness
dc.subjectdiabetic macular edema
dc.subjectdrug efficacy
dc.subjecteye surgery
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectlaser therapy
dc.subjectmacular volume
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmicropulse laser treatment
dc.subjectoptical coherence tomography
dc.subjectpars plana vitrectomy
dc.subjectretrospective study
dc.subjectvisual acuity
dc.subjectcomplication
dc.subjectdiabetes mellitus
dc.subjectdiabetic retinopathy
dc.subjectintravitreal drug administration
dc.subjectlaser
dc.subjectlaser coagulation
dc.subjectmacular edema
dc.subjectprocedures
dc.subjecttreatment outcome
dc.titleEfficacy of subthreshold micropulse laser combined with ranibizumab in the treatment of diabetic macular edema
dc.typeArticle

Files

Collections

Scopus Koleksiyonu